SEATTLE, Nov. 30, 2023 /PRNewswire/ -- Presage Biosciences, a pioneering translational oncology company whose mission is to use CIVO and spatial molecular profiling to understand the complexity of drug response in the tumor microenvironment (TME), has entered into an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company.

西雅图，2023年11月30日/PRNewswire/-Presage Biosciences，一家开创性的转化肿瘤学公司，其使命是使用CIVO和空间分子谱分析来了解肿瘤微环境（TME）中药物反应的复杂性，已签订与全球生物制药公司AstraZeneca（LSE/STO/Nasdaq:AZN）达成协议。

According to the agreement, Presage's platform will be used by AstraZeneca in translational analysis to evaluate several investigational bispecific antibody combinations in samples taken from head and neck cancer patients. The work will contribute to advancing AstraZeneca's growing portfolio of immuno-oncology agents looking to harness the immune system against cancer..

根据协议，Presage的平台将被阿斯利康用于转化分析，以评估从头颈癌患者采集的样品中的几种研究性双特异性抗体组合。这项工作将有助于推动阿斯利康不断增长的旨在利用免疫系统对抗癌症的免疫肿瘤药物组合。。

Rich Klinghoffer, PhD, Chief Executive Officer of Presage, said: 'Prior studies have demonstrated that the CIVO platform provides accurate guidance about the therapeutic potential of novel agents in the only context that matters: Fully intact patient tumors. We are very pleased to be working with an innovator like AstraZeneca and supporting their quest to discover, develop, and deliver transformative medicines to patients.'.

Presage首席执行官Rich Klinghoffer博士说：“之前的研究表明，CIVO平台在唯一重要的背景下提供了关于新药治疗潜力的准确指导：完全完整的患者肿瘤。我们非常高兴与阿斯利康等创新者合作，支持他们向患者发现，开发和提供变革性药物的追求。

Earlier this month, Presage presented results from a completed Phase 0 study evaluating Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) alone and in combination with other immune-oncology agents at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting. The study enrolled patients across six US-based cancer centers in both soft tissue sarcoma and head and neck cancer.

本月早些时候，Presage提供了一项完成的0期研究结果，该研究评估了默克抗PD-1疗法KEYTRUDA®（pembrolizumab）单独使用以及与癌症免疫治疗学会（SITC）2023年会上的其他免疫肿瘤药物联合使用。该研究纳入了美国六个癌症中心的软组织肉瘤和头颈部癌症患者。

Study data highlight the importance of evaluating novel therapies in patient tumors and revealed a contradiction between results from in-vivo animal studies versus results in the intact TME..

研究数据强调了评估患者肿瘤新疗法的重要性，并揭示了体内动物研究结果与完整TME结果之间的矛盾。。

'For too long, we have put our trust in laboratory models of cancer that do not capture the complexity of the intact TME,' said Klinghoffer. 'The CIVO technology was developed to address this fundamental issue in cancer drug development and the results from this study demonstrate the true power of our platform - the ability to know, early in development, how a drug impacts patient tumors.'.

“太长时间以来，我们一直相信癌症的实验室模型不能捕捉完整TME的复杂性，”Klinghoffer说开发CIVO技术是为了解决癌症药物开发中的这一基本问题，本研究的结果证明了我们平台的真正力量-在开发早期了解药物如何影响患者肿瘤的能力。

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

KEYTRUDA®是美国新泽西州拉威市默克公司股份有限公司子公司默克夏普多姆有限责任公司的注册商标。

About CIVO

关于CIVO

Clinical In Vivo Oncology (CIVO) is Presage's patented platform that enables multiplexed intratumoral microdosing and generation of deep spatial biology insights. The platform enables evaluation of up to eight distinct and trackable drugs and drug combinations simultaneously. Presage's CIVO technology and analysis capabilities are unparalleled at providing insight into drug-exposed areas of the intact tumor microenvironment.

临床体内肿瘤学（CIVO）是Presage的专利平台，可实现多重肿瘤内微量给药并产生深层空间生物学见解。该平台可以同时评估多达八种不同的可追踪药物和药物组合。Presage的CIVO技术和分析能力无与伦比，可以深入了解完整肿瘤微环境的药物暴露区域。

Presage is pairing the use of CIVO with molecular profiling technologies in Phase 0 trials in order to inform and de-risk drug development..

Presage正在0期临床试验中将CIVO与分子谱分析技术结合使用，以便为药物开发提供信息和降低风险。。

About Presage

关于Presage

Presage Biosciences is a translational oncology company dedicated to understanding the complexity of drug response in the tumor microenvironment. Presage partners with oncology-focused pharmaceutical companies through strategic alliances along with other innovators who are at the forefront of spatial biology and oncology drug development.

Presage Biosciences是一家转化肿瘤学公司，致力于了解肿瘤微环境中药物反应的复杂性。Presage通过战略联盟与以肿瘤学为重点的制药公司合作，以及处于空间生物学和肿瘤药物开发前沿的其他创新者。

Presage is privately held and based in Seattle. For more information, visit www.presagebio.com..

Presage是私营的，总部设在西雅图。欲了解更多信息，请访问www.presagebio.com。。

SOURCE Presage Biosciences Inc

来源Presage Biosciences Inc